Skip to main content
Top
Published in: BMC Gastroenterology 1/2012

Open Access 01-12-2012 | Research article

Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study

Authors: Geert Bezemer, Arthur R Van Gool, Elke Verheij-Hart, Bettina E Hansen, Yoav Lurie, Juan I Esteban, Martin Lagging, Francesco Negro, Stefan Zeuzem, Carlo Ferrari, Jean-Michel Pawlotsky, Avidan U Neumann, Solko W Schalm, Robert J de Knegt, for the DITTO-HCV Study Group

Published in: BMC Gastroenterology | Issue 1/2012

Login to get access

Abstract

Background

Hepatitis C decreases health related quality of life (HRQL) which is further diminished by antiviral therapy. HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study).

Methods

The Short Form (SF)-36 Health Survey was administered at baseline (n = 192) and 24 weeks after the end of therapy (n = 128).

Results

At baseline HRQL was influenced by age, participating center, severity of liver disease and income. Exploring the course of HRQL (scores at follow up minus baseline), only the dimension general health increased. In this dimension patients with a relapse or sustained response differed from non-responders. Men and women differed in the dimension bodily pain. Treatment schedule did not influence the course of HRQL.

Conclusions

Main determinants of HRQL were severity of liver disease, age, gender, participating center and response to treatment. Our results do not exclude a more profound negative impact of individualized treatment compared to standard, possibly caused by higher doses and extended treatment duration in the individualized group. Antiviral therapy might have a more intense and more prolonged negative impact on females.
Appendix
Available only for authorised users
Literature
1.
go back to reference Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998, 27: 209-212. 10.1002/hep.510270132.CrossRefPubMed Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998, 27: 209-212. 10.1002/hep.510270132.CrossRefPubMed
2.
go back to reference Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005, 41: 790-800. 10.1002/hep.20659.CrossRefPubMed Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005, 41: 790-800. 10.1002/hep.20659.CrossRefPubMed
3.
go back to reference Castera L, Constant A, Bernard PH, de Ledinghen V, Couzigou P: Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol. 2006, 12: 1545-1550.CrossRefPubMedPubMedCentral Castera L, Constant A, Bernard PH, de Ledinghen V, Couzigou P: Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol. 2006, 12: 1545-1550.CrossRefPubMedPubMedCentral
4.
go back to reference Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N: The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999, 30: 1299-1301. 10.1002/hep.510300504.CrossRefPubMed Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N: The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999, 30: 1299-1301. 10.1002/hep.510300504.CrossRefPubMed
5.
go back to reference Niederau C, Bemba G, Kautz A: [Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany--socioeconomic aspects in hepatitis C]. Z Gastroenterol. 2006, 44: 305-317. 10.1055/s-2006-926510.CrossRefPubMed Niederau C, Bemba G, Kautz A: [Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany--socioeconomic aspects in hepatitis C]. Z Gastroenterol. 2006, 44: 305-317. 10.1055/s-2006-926510.CrossRefPubMed
6.
go back to reference Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008, 9: 46-56. 10.1038/nrn2297.CrossRefPubMedPubMedCentral Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008, 9: 46-56. 10.1038/nrn2297.CrossRefPubMedPubMedCentral
7.
go back to reference Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, Ahl B, Manns MP, Boker KW: Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004, 41: 845-851. 10.1016/j.jhep.2004.07.022.CrossRefPubMed Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, Ahl B, Manns MP, Boker KW: Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004, 41: 845-851. 10.1016/j.jhep.2004.07.022.CrossRefPubMed
8.
go back to reference Bonkovsky HL, Woolley JM: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999, 29: 264-270. 10.1002/hep.510290124.CrossRefPubMed Bonkovsky HL, Woolley JM: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999, 29: 264-270. 10.1002/hep.510290124.CrossRefPubMed
9.
go back to reference Ware JE, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology. 1999, The Interventional Therapy Group, 30: 550-555. 10.1002/hep.510300203. Ware JE, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology. 1999, The Interventional Therapy Group, 30: 550-555. 10.1002/hep.510300203.
10.
go back to reference McHutchison JG, Ware JE, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP, Hepatitis Interventional Therapy Group: The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001, 34: 140-147.CrossRefPubMed McHutchison JG, Ware JE, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP, Hepatitis Interventional Therapy Group: The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001, 34: 140-147.CrossRefPubMed
11.
go back to reference Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, trejo-Estrada R, Horta E, Vale A, Wintfield N, green J: The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004, 40: 675-681. 10.1016/j.jhep.2003.12.014.CrossRefPubMed Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, trejo-Estrada R, Horta E, Vale A, Wintfield N, green J: The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004, 40: 675-681. 10.1016/j.jhep.2003.12.014.CrossRefPubMed
12.
go back to reference Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU, DITTO-HCV Study Group: International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005, 43: 250-257. 10.1016/j.jhep.2005.05.016.CrossRefPubMed Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU, DITTO-HCV Study Group: International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005, 43: 250-257. 10.1016/j.jhep.2005.05.016.CrossRefPubMed
13.
go back to reference Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995, 33 (Suppl): AS264-79.PubMed Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995, 33 (Suppl): AS264-79.PubMed
14.
go back to reference Wessely S, Pariante C: Fatigue, depression and chronic hepatitis C infection. Psychol Med. 2002, 32: 1-10.CrossRefPubMed Wessely S, Pariante C: Fatigue, depression and chronic hepatitis C infection. Psychol Med. 2002, 32: 1-10.CrossRefPubMed
15.
go back to reference Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM: Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007, 52: 2531-2539. 10.1007/s10620-006-9708-x.CrossRefPubMed Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM: Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007, 52: 2531-2539. 10.1007/s10620-006-9708-x.CrossRefPubMed
16.
go back to reference Ware JE, Kosinski M, Gandek B: SF-36 Health Survey Manual and Interpretation Guide. 1993, Boston, MA: New England Medical Center, The Health Institute Ware JE, Kosinski M, Gandek B: SF-36 Health Survey Manual and Interpretation Guide. 1993, Boston, MA: New England Medical Center, The Health Institute
17.
go back to reference Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998, 51: 1055-1068. 10.1016/S0895-4356(98)00097-3.CrossRefPubMed Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998, 51: 1055-1068. 10.1016/S0895-4356(98)00097-3.CrossRefPubMed
18.
go back to reference Lewin-Epstein N, Sagiv-Schifter T, Shabtai EL, Shmueli A: Validation of the 36-item short-form Health Survey (Hebrew version) in the adult population of Israel. Med Care. 1998, 36: 1361-1370. 10.1097/00005650-199809000-00008.CrossRefPubMed Lewin-Epstein N, Sagiv-Schifter T, Shabtai EL, Shmueli A: Validation of the 36-item short-form Health Survey (Hebrew version) in the adult population of Israel. Med Care. 1998, 36: 1361-1370. 10.1097/00005650-199809000-00008.CrossRefPubMed
19.
go back to reference Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R: Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004, 11: 243-250. 10.1111/j.1365-2893.2004.00490.x.CrossRefPubMed Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R: Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004, 11: 243-250. 10.1111/j.1365-2893.2004.00490.x.CrossRefPubMed
20.
go back to reference Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH, PROACTIVE Study Group: Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004, 40: 1450-1458. 10.1002/hep.20482.CrossRefPubMed Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH, PROACTIVE Study Group: Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004, 40: 1450-1458. 10.1002/hep.20482.CrossRefPubMed
21.
go back to reference Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group: Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007, 46: 420-431. 10.1016/j.jhep.2006.10.009.CrossRefPubMed Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group: Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007, 46: 420-431. 10.1016/j.jhep.2006.10.009.CrossRefPubMed
22.
go back to reference Wagner AK, Gandek B, Aaronson NK, Acquadro C, Alonso J, Apolone G, Bullinger M, Bjorner J, Fukuhara S, Kaasa S, Leplege A, Sullivan M, Waud-Dauphinee S, Ware JE: Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998, 51: 925-932. 10.1016/S0895-4356(98)00083-3.CrossRefPubMed Wagner AK, Gandek B, Aaronson NK, Acquadro C, Alonso J, Apolone G, Bullinger M, Bjorner J, Fukuhara S, Kaasa S, Leplege A, Sullivan M, Waud-Dauphinee S, Ware JE: Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998, 51: 925-932. 10.1016/S0895-4356(98)00083-3.CrossRefPubMed
23.
go back to reference Bullinger M, Alonso J, Apolone G, Leplege A, Sullivan M, Wood-Dauphinee S, Gandek B, Wagner A, Aaronson N, Bech P, Fukuhara S, Kasa S, Ware JE: Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol. 1998, 51: 913-923. 10.1016/S0895-4356(98)00082-1.CrossRefPubMed Bullinger M, Alonso J, Apolone G, Leplege A, Sullivan M, Wood-Dauphinee S, Gandek B, Wagner A, Aaronson N, Bech P, Fukuhara S, Kasa S, Ware JE: Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol. 1998, 51: 913-923. 10.1016/S0895-4356(98)00082-1.CrossRefPubMed
Metadata
Title
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
Authors
Geert Bezemer
Arthur R Van Gool
Elke Verheij-Hart
Bettina E Hansen
Yoav Lurie
Juan I Esteban
Martin Lagging
Francesco Negro
Stefan Zeuzem
Carlo Ferrari
Jean-Michel Pawlotsky
Avidan U Neumann
Solko W Schalm
Robert J de Knegt
for the DITTO-HCV Study Group
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2012
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-12-11

Other articles of this Issue 1/2012

BMC Gastroenterology 1/2012 Go to the issue